ProKidney Corp (NASDAQ: PROK) 52-Week High Located At $7.13, Forget The Dips, Just Ride The Rips

ProKidney Corp (NASDAQ:PROK) does about 12.92M shares in volume on a normal day but saw 3166509 shares change hands in the recent trading day. The company now has a market cap of 901.54M USD. Its current market price is $3.08, marking a decrease of -6.38% compared to the previous close of $3.29. The 52 week high reached by this stock is $7.13 whilst the lowest price level in 52 weeks is $0.46. The script in recent trading has seen the stock touch a high of $6 and a low of $3.

ProKidney Corp (PROK) has a 20-day trading average at $2.87 and the current price is -56.80% off the 52-week high compared with 569.13% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.62 and its 200-day simple moving average is $1.48. If we look at the stock’s price movements over the week, volatility stands at 12.22%, which increases to 38.64% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 56.83 to suggest the stock is neutral.

6 analysts observing the ProKidney Corp (PROK) stock have set the 12-month price targets for the company’s shares at between $3 and $6. The consensus objective for the share price is $5.60, suggesting that the stock has a potential upside of 45.0% over the period. The median price target is 38.4% away from the current levels at $5.

FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 30, 2025 when BofA Securities downgraded the stock to “Underperform” and issued a price target of $1. Guggenheim initiated its price target at $6.

The current price level is 7.41%, 90.01%, and 108.47% away from its SMA20, SMA50, and SMA200 respectively, with the PROK price moving below the 50-day SMA on current market day. ProKidney Corp (PROK) stock is down -4.35% over the week and 326.06% over the past month. Its price is 46.67% year-to-date and 82.25% over the past year.

Its 12-month price target is $5. To reach the target analysts have set, the stock logically needs to grow 45.0 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.

The beta has a value of 2.24. Price to sales ratio is 2908.20.

Comet Reports
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.